Head-to-head · Cost-Efficiency Index
PeptidesRx vs SkyRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
PeptidesRx
Cost-first shoppers who want itemized per-vial pricing across every dose tier, for shoppers who read past the '1-week starter' teaser price.
Visit PeptidesRxSkyRx
Shoppers willing to commit and prepay a full year upfront in exchange for a lower blended monthly rate.
Visit SkyRxThe verdict
PeptidesRx and SkyRx tie on the Cost-Efficiency Index at 55/100, so neither wins outright on the numbers. For most shoppers we'd start with PeptidesRx (ranked #343, a hair above #346) — Cost-first shoppers who want itemized per-vial pricing across every dose tier, for shoppers who read past the '1-week starter' teaser price. But SkyRx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs PeptidesRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | PeptidesRx | SkyRx |
|---|---|---|
| Cost-Efficiency Index | 55/100 | 55/100 |
| Semaglutide / mo | $321/mo (10 mg dose, compounded) | $199/mo (compounded) |
| Tirzepatide / mo | $576/mo (40 mg dose, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $3,852 | $2,388 |
| Tirzepatide / yr (modeled) | $6,912 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #343 | #346 |
PeptidesRx
55/100Where the value is
- Confirmed legitimate clinical telehealth service — licensed provider consultation required before any prescription, with no 'research use only' disclaimer anywhere
- Every dose tier for both drugs is individually priced and published, more granular transparency than most competitors in this batch
- Cancel-anytime, no long-term contract on any SKU
The tradeoffs
- The homepage's 'From $185/mo' and 'From $304/mo' teaser prices are for vials the catalog itself labels a '1-week starter' supply — the genuine 4-week tier costs 69-89% more, and this gap is easy to miss since every tier bills as a monthly auto-renewal regardless of the vial's actual duration
- No compounding pharmacy is individually named, only 'PCAB-accredited US pharmacies'
SkyRx
55/100Where the value is
- Simple, single headline price displayed on the weight-loss page
- Claims LegitScript certification
- Straightforward telehealth intake flow
The tradeoffs
- The '$199/mo' price is a 12-month prepay rate, not a cancel-anytime monthly price -- a major disclosure trap
- Tirzepatide not yet available ('coming soon'), so half the category is unpriced
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.